Tag: ZIP6
First-Patient Dosed with BRY812 in Phase I Trial
A first patient has been dosed in a Phase I Clinical trial of BRY812, a third-generation antibody-drug conjugate (ADC) targeting LIV-1 being developed by BioRay Pharmaceutical Co., for the treatment of advanced malignant tumors.
BioRay’s IND Application for BRY812, Accepted by the China National Medical...
The China National Medical Products Administration (NMPA) has accepted the Investigational New Drug (IND) application for BRY812, a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the treatment of advanced malignant tumors (Acceptance No. CXSL2300366). The investigational drug is being developed by Shanghai-based BioRay Pharmaceutical Co.
